###begin article-title 0
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
###end article-title 0
###begin p 1
A.N. Houghton and J.D. Wolchok contributed equally to this paper.
###end p 1
###begin p 2
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1010 1011 1010 1011 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Expansion and recruitment of CD4+ Foxp3+ regulatory T (T reg) cells are mechanisms used by growing tumors to evade immune elimination. In addition to expansion of effector T cells, successful therapeutic interventions may require reduction of T reg cells within the tumor microenvironment. We report that the combined use of the alkylating agent cyclophosphamide (CTX) and an agonist antibody targeting the co-stimulatory receptor OX40 (OX86) provides potent antitumor immunity capable of regressing established, poorly immunogenic B16 melanoma tumors. CTX administration resulted in tumor antigen release, which after OX86 treatment significantly enhanced the antitumor T cell response. We demonstrated that T reg cells are an important cellular target of the combination therapy. Paradoxically, the combination therapy led to an expansion of T reg cells in the periphery. In the tumor, however, the combination therapy induced a profound T reg cell depletion that was accompanied by an influx of effector CD8+ T cells leading to a favorable T effector/T reg cell ratio. Closer examination revealed that diminished intratumoral T reg cell levels resulted from hyperactivation and T reg cell-specific apoptosis. Thus, we propose that CTX and OX40 engagement represents a novel and rational chemoimmunotherapy.
###end p 2
###begin p 3
###xml 232 233 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 239 240 239 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 257 258 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">3</xref>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
Clinically relevant cancers must establish efficient mechanisms of escaping destruction by the immune system. One of the most successful strategies of tumor-induced immune evasion is the recruitment, expansion, and activation of CD4+ Foxp3+ T reg cells (1, 2). T reg cells can potently inhibit immune responses and constitute a major barrier for eliciting effective antitumor immunity (3). Cancer patients suffering from a variety of malignancies have elevated numbers of tumor-associated T reg cells, and increased T reg cell levels correlate with poor prognosis (4-10).
###end p 3
###begin p 4
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
Not surprisingly, the inactivation or depletion of T reg cells has been actively pursued as means to develop more potent immune therapies. Depletion of T reg cells has been accomplished with alkylating agents such as cyclophosphamide (CTX) (11-17). As a chemotherapeutic drug, CTX is administered clinically at doses that directly kill tumor cells. However, immunologists have known for decades that CTX has significant effects on the immune system that can promote a favorable antitumor immune response (14, 18).
###end p 4
###begin p 5
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">22</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">25</xref>
In addition to specific effects of CTX on T reg cells, lymphocytes recovering from CTX-induced lymphopenia undergo homeostatic proliferation that can activate tumor-specific T cells (19). Reconstitution from CTX-induced lymphopenia is associated with elevated levels of numerous proinflammatory cytokines, which favors an antitumor immune response (20, 21). Moreover, direct tumor cell death can be associated with tissue necrosis and the release of danger signals that enhance tumor antigen cross-presentation and cross-priming (22, 23). To increase antitumor immune responses, CTX has been successfully combined with vaccination and adoptive immunotherapy strategies (chemoimmunotherapy) in multiple modalities and tumor models (24, 25).
###end p 5
###begin p 6
###xml 143 144 143 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 280 281 280 281 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 411 412 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
OX40 is a co-stimulatory molecule and member of the TNFR family constitutively expressed on T reg cells and inducibly expressed by effector CD4+ T cells upon activation (26). Signaling through OX40 up-regulates the expression of antiapoptotic Bcl-2 family members, Bcl-2 and Bcl-XL, leading to increased clonal expansion and memory responses (17). OX40 signaling can also provide co-stimulation to activated CD8+ T, NK, and NKT cells (27-30).
###end p 6
###begin p 7
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 305 306 305 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 311 312 311 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 612 613 612 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 672 674 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 676 678 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">35</xref>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
###xml 330 334 <span type="species:ncbi:10090">mice</span>
Although the function of OX40 has been established for effector CD4+ and CD8+ T cells, the biological role that OX40 plays on T reg cells is still controversial. Early reports have shown that OX40 ligation is crucial for T reg cell homeostasis (31). Young mice deficient in OX40 have reduced levels of CD4+ CD25+ T reg cells, and mice overexpressing OX40L possess elevated levels in the spleen and thymus. However, engaging OX40 can abrogate the T reg cell suppressive function and down-regulate Foxp3 expression (31-34). Additionally, it has been reported that OX40 ligation prevents the conversion of naive CD4+ T cells into T reg cells induced by TGF-beta and antigen (33, 35).
###end p 7
###begin p 8
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">36</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">39</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib45">45</xref>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 657 662 <span type="species:ncbi:10090">mouse</span>
Given that OX40 engagement can potently stimulate T cells and potentially inhibit T reg cells, it has been successfully used in the treatment of a variety of transplantable tumors in mice (34, 36). Overexpression of OX40L in tumor cell lines and dendritic cells induced substantial antitumor immunity (37-39). The triggering of OX40 with recombinant soluble OX40L or the anti-OX40 agonist monoclonal antibody OX86 are additional strategies proven to be effective in treating immunogenic tumors (40-45). However, targeting OX40 alone or in combination with other therapeutic approaches has only marginal effects on less immunogenic, more clinically relevant mouse tumors.
###end p 8
###begin p 9
###xml 342 343 342 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 351 352 351 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 872 873 872 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 212 217 <span type="species:ncbi:10090">mouse</span>
We hypothesized that OX40 ligation after administration of CTX would provide strong antitumor immunity. Indeed, we found that OX86 in combination with CTX synergized to mediate the regression of established, B16 mouse melanoma tumors. We demonstrate that CTX treatment resulted in the release of tumor antigens capable of priming effector CD4+ and CD8+ T cells, and that OX40 engagement amplified these responses. Furthermore, we show that the combination therapy targets T reg cells, inducing previously uncharacterized changes in this population. Unexpectedly, OX86 administration increased the number of T reg cells in the periphery, an effect that was exacerbated when OX86 was administered with CTX. In contrast, the combination therapy significantly reduced the number of T reg cells infiltrating the tumor, with a substantial, increased infiltration of effector CD8+ T cells. Closer mechanistic examination revealed that the combination therapy resulted in T reg cell-specific apoptosis, which accounted for the reduced intratumoral infiltration. Thus, we report a potent, clinically translatable chemoimmunotherapy and provide insight into a novel mechanism that involves elimination of T reg cells in the tumor microenvironment.
###end p 9
###begin title 10
RESULTS
###end title 10
###begin title 11
CTX synergizes with OX40 engagement to promote potent antitumor immunity
###end title 11
###begin p 12
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib43">43</xref>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib44">44</xref>
###xml 438 446 438 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 482 490 482 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 250 254 <span type="species:ncbi:10090">Mice</span>
Administration of OX86 yields weak, ineffective responses to poorly immunogenic tumors (43, 44). We sought to increase the potency of OX86 treatment by combining it with CTX, a drug with both immune-enhancing properties and direct antitumor effects. Mice with 6-d established B16 tumors were treated with a single 250 mg/kg dose of CTX followed by 0.5 mg OX86 the next day. Treatment resulted in the survival of 75% of animals at day 50 (Fig. 1 A) and regressed established tumors (Fig. 1 B). Neither therapy alone provided significant tumor protection.
###end p 12
###begin p 13
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OX40 engagement synergizes with CTX to provide potent antitumor immunity.</bold>
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 447 448 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 688 689 688 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
###xml 291 294 <span type="species:ncbi:10116">rat</span>
###xml 441 445 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
OX40 engagement synergizes with CTX to provide potent antitumor immunity. (A) C57BL/6 mice (n = 15 per group) were injected intradermally in the flank with a lethal dose of B16 melanoma. On day 6, once tumors were palpable, CTX or PBS was injected. On day 7, mice were injected with OX86 or rat IgG. The Kaplan-Meier plot depicts overall survival. Similar results were obtained from four independent experiments. **, P = 0.0061. (B) C57BL/6 mice (n = 10-15 per group) were treated as in A and tumor area was measured periodically. Plots represent the tumor diameter of individual mice for each treatment. Similar results were obtained from four independent experiments. (C) C57BL/6 mice (n = 10 per group) were treated as in A. In some groups, OX86 injection was replaced with 9D9 (anti-CTLA4) or FGK45 (anti-CD40). Tumor area was measured periodically. Results represent mean tumor areas +/- SEM for each treatment
###end p 13
###begin p 14
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib46">46</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">47</xref>
###xml 455 463 455 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
To evaluate the clinical potential of OX86 and CTX therapy, we compared it with the combination of CTX and monoclonal antibodies with proven efficacy in preclinical models, such as anti-CTLA4 (9D9) or anti-CD40 (FGK45) (46, 47). We found that OX86 in combination with CTX showed a much higher potency than any of the other treatments. Combination therapy with FGK45 had a comparable effect to CTX alone, whereas the 9D9 combination provided some benefit (Fig. 1 C). Furthermore, the combination therapy promoted the regression of established tumors and/or significantly prolonged survival in other poorly immunogenic tumor models (4T1 mammary carcinoma, Lewis lung carcinoma, and Tramp C2 prostate adenocarcinoma; unpublished data). These experiments demonstrate that administration of a single dose of CTX synergizes with anti-OX40 antibody to provide antitumor immunity that can eradicate poorly immunogenic tumors.
###end p 14
###begin title 15
CTX-induced tumor destruction releases B16 tumor antigen that is capable of priming an antitumor immune response in the presence of OX86
###end title 15
###begin p 16
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib48">48</xref>
###xml 692 700 692 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 380 384 <span type="species:ncbi:10090">Mice</span>
###xml 909 913 <span type="species:ncbi:10090">mice</span>
We hypothesized that partial destruction of the tumor by CTX releases antigen capable of priming a tumor-specific response, and that OX86 enhances the function of tumor-specific T cells. To test this hypothesis, we transferred CFSE-labeled TCR transgenic CD8+ T cells specific for the melanoma antigen gp100 (pmel-1 cells) (48) into tumor-bearing mice pretreated with CTX or PBS. Mice were injected the next day with OX86 or IgG, and 5 d later proliferation by CFSE dilution was measured in the tumor draining LN (TDLN) or at a distant LN (non-DLN) by flow cytometry. In the TDLN, pmel-1 cells from the CTX plus OX86-treated group showed higher proliferation than any of the therapies alone (Fig. 2 A). Although some proliferation was found at the non-DLN in both CTX-treated groups (presumably as a result of homeostatic proliferation caused by CTX administration), a preferential proliferation was found in mice that received CTX plus OX86 compared with animals that received CTX plus IgG. Thus, proliferation of tumor-specific T cells was observed primarily in TDLN compared with non-DLN.
###end p 16
###begin p 17
###xml 0 110 0 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tumor destruction by CTX provides antigen that can prime an antitumor immune response in the presence of OX86.</bold>
###xml 136 137 136 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 320 321 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 347 348 347 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 583 584 583 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 589 590 589 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 602 603 602 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 716 717 716 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 948 949 948 949 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 957 958 957 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1078 1079 1072 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 251 255 <span type="species:ncbi:10090">mice</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
###xml 383 386 <span type="species:ncbi:10116">rat</span>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
###xml 710 714 <span type="species:ncbi:10090">mice</span>
###xml 821 825 <span type="species:ncbi:10090">mice</span>
###xml 888 891 <span type="species:ncbi:10116">rat</span>
Tumor destruction by CTX provides antigen that can prime an antitumor immune response in the presence of OX86. (A) C57BL/6 Thy1.2 mice (n = 4 per group) were injected with five times the lethal dose of B16 tumor cells in Matrigel. On day 6, groups of mice were treated with CTX or PBS. On day 7, all mice received 2 x 106 purified CFSE-labeled CD8+ pmel-1 cells (Thy1.1) and OX86 or rat IgG. On day 13, mice were sacrificed, and a single-cell suspension was prepared from inguinal (TDLN) or contralateral cervical LN (non-DLN) and analyzed by flow cytometry. Cells were gated on DAPI-, CD8+, and Thy1.1+. One representative plot from three independent experiments is shown (percentages are shown). (B) C57BL/6 mice (n = 5 per group) were either injected with B16-Matrigel or left as non-tumor-bearing controls. On day 6, mice were injected with CTX, followed by administration of OX86 or rat IgG on day 7. 21 d after tumor inoculation, purified CD8+ and CD4+ T cells from pooled spleens were tested by IFN-gamma ELISPOT. Values represent mean numbers of spots per well +/- SEM (n = 3-4 wells). Data shown are representative of four independent experiments.
###end p 17
###begin p 18
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 273 274 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 281 282 277 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 412 420 408 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 B</xref>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 310 314 <span type="species:ncbi:10090">mice</span>
To further substantiate our hypothesis, we purified CD8+ and CD4+ T cells from spleens of tumor-bearing or naive mice subjected to the combination therapy and tested their ability to react against B16 and melanoma-specific peptides in IFN-gamma ELISPOT assays. Only the CD4+ or CD8+ T cells from tumor-bearing mice treated with the combination therapy responded to B16 or APCs pulsed with B16-specific peptides (Fig. 2 B). These results strongly suggest that, upon CTX administration, antigen is made available for priming by drug-induced tumor destruction, and that OX86 aids in the expansion of antitumor T cells.
###end p 18
###begin title 19
CTX administration modulates the expression of OX40 on T reg cells
###end title 19
###begin p 20
###xml 501 502 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 555 556 555 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 566 574 566 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 855 856 855 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 862 863 862 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 933 934 933 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 940 941 940 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 951 959 951 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 191 195 <span type="species:ncbi:10090">Mice</span>
Only cells expressing OX40 can be directly receptive to the effects of an agonist anti-OX40 antibody. Hence, we investigated how CTX affects the expression of OX40 in different cell subsets. Mice were injected with CTX and spleens were harvested on days 0, 1, 2, 4, 7, 11, 17, and 24 after injection. Single-cell suspensions were prepared from spleens and analyzed by flow cytometry for OX40 expression in different cell populations. We found that CTX modulated the expression of OX40 primarily in CD4+ T cells, but little or no change was observed in CD8+ T cells (Fig. 3 A). OX40 expression was down-regulated at the nadir of CTX-induced cytopenia (day 4) and was up-regulated as cells were recovering from lymphopenia (day 11) compared with baseline expression. On closer examination, we observed that OX40 expression was modulated primarily in the CD4+ Foxp3+ T reg cell population, with minimal changes in OX40 expression in CD4+ Foxp3- T cells (Fig. 3 B). These results suggest that T reg cells are likely to be a direct target of the combination therapy, because CTX administration modulated the expression of OX40 most dramatically in this subset.
###end p 20
###begin p 21
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTX administration modulates OX40 expression on T reg cells.</bold>
###xml 288 289 288 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 309 310 309 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 318 319 318 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 439 440 439 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 445 446 445 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 454 455 454 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 460 461 460 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 69 73 <span type="species:ncbi:10090">mice</span>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
CTX administration modulates OX40 expression on T reg cells. C57BL/6 mice were injected with CTX. Groups of four mice were sacrificed on days 0, 1, 2, 4, 7, 11, 17, and 24 after CTX injection, and splenocytes were analyzed by flow cytometry for OX40 expression. (A) The percentage of OX40+ events gated on CD4+ and CD8+ T cells. A representative histogram depicting day 0 is shown (right). (B) OX40 mean fluorescence intensity (MFI) of CD4+Foxp3+ and CD4+Foxp3- T cells. A representative histogram depicting day 0 is shown. Values represent means +/- SEM. The experiment was repeated three times with similar results.
###end p 21
###begin title 22
Preferential binding of OX86 to T reg cells after CTX administration
###end title 22
###begin p 23
###xml 412 420 412 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 475 476 475 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 510 511 510 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 664 665 640 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 775 776 739 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 870 878 834 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 B</xref>
###xml 1179 1181 1143 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib49">49</xref>
###xml 1183 1185 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib50">50</xref>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
To determine the in vivo cellular targets responsible for the effects of the combination therapy, we injected biotinylated OX86 into tumor-bearing mice treated with CTX. On day 21 after tumor challenge, single-cell suspensions prepared from tumor, TDLN, and spleen were stained ex vivo with streptavidin-PE (strep-PE) and analyzed by flow cytometry for the presence of OX86-biotin in different cell populations. Fig. 4 A shows that OX86-biotin was bound preferentially to CD4+ T cells. Approximately 50% of CD4+ T cells in the tumor, approximately20% in the TDLN, and approximately30% in the spleen were OX86-biotin positive, whereas only a small percentage of CD8+ cells bound OX86-biotin in the tumor (approximately3%). When we examined OX86-biotin binding to different CD4+ subsets, we found that OX86 was primarily bound to T reg cells in each of the organs tested (Fig. 4 B). These results confirm the previous observation that T reg cells are a direct cellular target of the CTX plus OX86 combination therapy. These results also validate early reports showing that OX86 does not deplete OX40-expressing cells and remains bound to its cellular target for prolonged periods (49, 50). We propose, then, that CTX may increase the availability and potency of OX86 by depleting cells important for antibody clearance, additionally explaining the basis for CTX and OX86 synergy.
###end p 23
###begin p 24
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Preferential binding of OX86 in vivo to T reg cells after CTX administration.</bold>
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 462 463 462 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 471 472 471 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 542 543 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 549 550 549 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 558 559 558 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 565 566 565 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
Preferential binding of OX86 in vivo to T reg cells after CTX administration. C57BL/6 mice (n = 3-4 per group) were inoculated with B16-Matrigel. On day 6, mice received CTX and were then injected with biotinylated OX86 or PBS on day 7. Single-cell suspensions were prepared on day 21 from tumor, TDLN, and spleen, and were stained with strep-PE in addition to phenotypic markers. The samples were analyzed by flow cytometry. (A) Representative histograms of CD4+ and CD8+ T cells (percentages are shown). (B) Representative histograms of CD4+ Foxp3+ and CD4+ Foxp3- T cells. The experiment was repeated two times with similar results.
###end p 24
###begin title 25
Combination therapy expands T reg cells in the periphery
###end title 25
###begin p 26
###xml 434 449 434 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, A and B</xref>
###xml 686 701 674 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, A and B</xref>
###xml 880 888 868 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 920 921 908 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 925 926 913 914 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 932 933 920 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1047 1048 1035 1036 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
###xml 254 257 <span type="species:ncbi:10116">rat</span>
###xml 620 624 <span type="species:ncbi:10090">mice</span>
Previous results show T reg cells to be a primary target of the CTX plus OX86 treatment. Therefore, we investigated the biological effects of the combination therapy on T reg cells in vivo. We injected groups of mice with CTX or PBS, followed by OX86 or rat IgG 1 d later, and analyzed populations of splenocytes at day 15. Interestingly, we found an increase in the percentage of T reg cells when OX86 or CTX was administered alone (Fig. 5, A and B). Moreover, T reg cell expansion was further amplified with the combination therapy, as we observed an approximately2.5-fold increase in the percentage of T reg cells in mice treated with CTX plus OX86 compared with control treatments (Fig. 5, A and B). T reg cell expansion was confirmed by the proliferation marker Ki67, where greater numbers of T reg cells stained positive with the combination therapy compared with controls (Fig. 5 A). Only a small increase in Ki67+ CD4+ Foxp3- cells was observed in the CTX-treated groups, presumably as a result of homeostatic proliferation of effector CD4+ T cells. Thus, the combination therapy leads to a T reg cell-specific expansion.
###end p 26
###begin p 27
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTX OX86 combination therapy induces T reg cell expansion.</bold>
###xml 73 74 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 298 299 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 305 306 305 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 314 315 314 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 411 412 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 429 430 429 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 150 153 <span type="species:ncbi:10116">rat</span>
CTX OX86 combination therapy induces T reg cell expansion. C57BL/6 mice (n = 4 per group) were injected with CTX or PBS on day 1 and received OX86 or rat IgG on day 2. On day 15, splenocytes were prepared and analyzed by flow cytometry. (A) Representative histogram showing the Ki67 profiles of CD4+ Foxp3+ and CD4+ Foxp3- T cells from different treatment groups (percentages are shown). (B) Percentage of Foxp3+ cells in the CD4+ gate with different treatments. The experiment was repeated five times with similar results. Horizontal bars represent means. *, P < 0.05.
###end p 27
###begin p 28
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">32</xref>
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 127 128 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 458 459 458 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 465 469 465 469 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eGFP</sub>
###xml 469 470 469 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
Recent reports have shown that OX40 engagement can block the suppressive function of Foxp3 T reg cells (32-34). We purified CD4+ CD25+ cells from treated mice and performed ex vivo suppression assays to test if this observation holds true for T reg cells expanded in vivo. We found no difference in the suppressive capabilities of T reg cells purified from mice treated with combination and control therapies (). Similar results were obtained when sorted CD4+ Foxp3eGFP+ cells were used in the assay (unpublished data).
###end p 28
###begin p 29
Overall, these results indicate that OX40 engagement promotes the expansion of bona fide T reg cells in vivo, an effect that is greatly amplified by the combination with CTX. This observation is quite puzzling given the potent antitumor effects of the combination therapy.
###end p 29
###begin title 30
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Combination therapy decreases T reg cells in the tumor concomitantly with an increased infiltration of CD8+ T cells that results in a favorable T effector/T reg cell ratio
###end title 30
###begin p 31
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib51">51</xref>
###xml 487 503 487 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 (A and C)</xref>
###xml 307 311 <span type="species:ncbi:10090">Mice</span>
###xml 383 386 <span type="species:ncbi:10116">rat</span>
Although elevated T reg cell levels have been associated with a clinically unfavorable prognosis (51), our data show an increase in the proliferation of splenic T reg cells after treatment. Therefore, we investigated the effect of the combination therapy on cells present within the tumor microenvironment. Mice bearing B16-Matrigel tumors were treated with CTX on day 6 and OX86 or rat IgG on day 7, and tumors and TDLNs were analyzed by flow cytometry 1 wk later (day 13). As shown in Fig. 6 (A and C), we observed a profound depletion of T reg cells in the tumor and TDLN in groups treated with CTX regardless of antibody treatment. This resulted in decreased absolute numbers of T reg cells at these sites (unpublished data).
###end p 31
###begin p 32
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 134 0 134 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTX OX86 combination therapy decreases the levels of tumor-infiltrating T reg cells concomitantly with CD8<sup>+</sup> T cell tumor infiltration.</bold>
###xml 155 156 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 599 600 599 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 623 624 623 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 667 668 667 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 681 682 681 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 763 764 763 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 794 795 794 795 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 892 895 892 895 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 902 903 902 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1011 1012 1011 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 1025 1026 1025 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1044 1047 1044 1047 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1117 1118 1117 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 149 153 <span type="species:ncbi:10090">mice</span>
###xml 219 223 <span type="species:ncbi:10090">mice</span>
###xml 274 277 <span type="species:ncbi:10116">rat</span>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
###xml 896 900 <span type="species:ncbi:10090">mice</span>
###xml 910 914 <span type="species:ncbi:10090">mice</span>
###xml 1061 1065 <span type="species:ncbi:10090">mice</span>
###xml 1149 1153 <span type="species:ncbi:10090">mice</span>
CTX OX86 combination therapy decreases the levels of tumor-infiltrating T reg cells concomitantly with CD8+ T cell tumor infiltration. (A-D) C57BL/6 mice (n = 3-5 per group) were inoculated with B16-Matrigel. On day 6, mice were injected with CTX or PBS followed by OX86 or rat IgG on day 7. Single-cell suspensions were prepared on day 13 or 21 from tumor and TDLN, and were analyzed by flow cytometry. Non-CTX-treated mice succumbed to disease before day 21. Representative histograms of CD4 versus Foxp3 cells for day 13 (A) and day 21 (B) are shown (percentages are shown). (C) Percentage of CD4+ T cells that are Foxp3+. (D, left) Representative histogram of CD8+ versus Foxp3+ cells in the tumor on day 21 (percentages are shown). (middle) Percentage of CD8+ T cells. (right) Ratio of CD8+ T cells/T reg cells. Experiments were repeated five times with similar results. (E) C57BL/6 OX40-/- mice (n = 4-5 mice per group) were injected with B16-Matrigel. On day 6, CTX was administered, and on day 7, 2 x 107 purified CD4+ T cells from OX40-/- or wild-type mice were i.v. injected. A control group received 3 x 107 splenocytes. On the same day, mice were injected with OX86. On day 12, tumors, TDLN, and spleens were analyzed by flow cytometry. The experiment was performed two times with similar results. Horizontal bars represent means. *, P < 0.05.
###end p 32
###begin p 33
###xml 219 220 207 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 416 431 392 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6, B and C</xref>
###xml 629 630 593 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 636 637 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 828 836 792 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 B</xref>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
To understand the antitumor synergy of CTX plus OX86, we evaluated the effect of the combination therapy on cells present within the tumor and TDLN 2 wk after treatment (day 21). We observed that approximately50% of CD4+ T cells infiltrating the tumor were T reg cells in the CTX plus IgG control group, whereas CTX plus OX86-treated mice showed a substantial reduction in T reg cell infiltration (approximately13%; Fig. 6, B and C). In contrast, the frequency of T reg cells present in the TDLN increased with the combination therapy compared with controls. We did find a modest increase of approximately30% in the number of CD4+ Foxp3- cells infiltrating the tumor; however, the combination therapy consistently decreased the absolute number of T reg cells in the tumor and increased T reg cell levels in the TDLN on day 21. (Fig. 6 B and not depicted).
###end p 33
###begin p 34
###xml 56 57 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 137 145 137 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 D</xref>
###xml 472 473 472 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib46">46</xref>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">52</xref>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 434 439 <span type="species:ncbi:9606">human</span>
###xml 452 457 <span type="species:ncbi:10090">mouse</span>
On day 21 we also observed a substantial increase in CD8+ T cells within tumors of mice that received CTX plus OX86 combination therapy (Fig. 6 D). Thus, the combination therapy decreased the numbers of tumor-infiltrating T reg cells while simultaneously increasing the levels of effector T cells. A decreased intratumoral T reg/T effector cell ratio is a hallmark of many successful immunotherapies, as demonstrated for a variety of human cancers and mouse tumor models (2, 46, 52).
###end p 34
###begin p 35
###xml 219 222 219 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 230 233 230 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 246 247 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 277 280 277 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 539 547 539 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 E</xref>
###xml 625 628 625 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 632 633 632 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 687 690 687 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 792 793 792 793 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 852 855 852 855 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 859 860 859 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 602 606 <span type="species:ncbi:10090">mice</span>
###xml 764 768 <span type="species:ncbi:10090">mice</span>
###xml 829 833 <span type="species:ncbi:10090">mice</span>
To test whether the lower numbers of infiltrating T reg cells in the tumor and the higher numbers in the periphery were caused by a direct effect of the combination therapy on T reg cells, we adoptively transferred OX40+/+ or OX40-/- purified CD4+ cells into tumor-bearing OX40-/- recipients that were treated with CTX. As a control, we included a group that received wild-type splenocytes. 4 h after adoptive transfer, OX86 was administered to all groups. 5 d later, spleens, TDLN, and tumors were analyzed by flow cytometry. As shown in Fig. 6 E, lower levels of T reg cells infiltrated the tumor in mice that received OX40+/+ CD4+ cells or wild-type splenocytes compared with the OX40-/- group. Higher levels of T reg cells were found in the spleen and TDLN of mice receiving wild-type CD4+ cells or splenocytes compared with mice that received OX40-/- CD4+ T cells. These results confirm that the therapy-induced changes in the T reg cell population are caused at least in part by the direct targeting of T reg cells.
###end p 35
###begin title 36
CTX plus OX86 increases T reg cell activation and apoptosis
###end title 36
###begin p 37
###xml 229 230 229 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 236 237 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib53">53</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">35</xref>
###xml 499 500 499 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 506 510 506 510 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eGFP</sub>
###xml 510 511 510 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 518 519 518 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 525 529 525 529 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eGFP</sub>
###xml 529 530 529 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 745 746 745 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 752 756 752 756 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eGFP</sub>
###xml 756 757 756 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 797 798 797 798 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 804 808 804 808 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eGFP</sub>
###xml 808 809 808 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 556 560 <span type="species:ncbi:10090">mice</span>
###xml 606 610 <span type="species:ncbi:10090">mice</span>
###xml 638 641 <span type="species:ncbi:10116">rat</span>
###xml 723 727 <span type="species:ncbi:10090">mice</span>
We next examined the mechanism leading to lower intratumoral T reg cell infiltration with CTX plus OX86 treatment. Several reports have demonstrated that the tumor microenvironment is conducive to the peripheral conversion of CD4+ Foxp3- to T reg cells (53). In addition, it was recently reported that OX40 engagement can block peripheral conversion of induced T reg cells (33, 35). To evaluate the possibility that OX86 might block peripheral conversion in our model, we transferred FACS-sorted CD4+ Foxp3eGFP+ or CD4+ Foxp3eGFP- cells into tumor-bearing mice that were pretreated with CTX. The next day, mice were injected with OX86 or rat IgG. 5 d after cell transfer, we found no tumor-induced peripheral conversion in mice that received CD4+ Foxp3eGFP- cells (). However, in recipients of CD4+ Foxp3eGFP+ cells, we noted increased accumulation of the transferred cells in the TDLN and decreased levels in the tumor. This is consistent with our previous observation and suggests that decreased T reg cell infiltration after combination therapy does not result from blocked peripheral conversion.
###end p 37
###begin p 38
###xml 242 250 242 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 A</xref>
###xml 400 408 400 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 B</xref>
###xml 794 802 794 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 C</xref>
###xml 868 870 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib54">54</xref>
###xml 1175 1177 1175 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib55">55</xref>
###xml 1292 1300 1292 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 D</xref>
###xml 1329 1330 1329 1330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1338 1339 1338 1339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1412 1420 1412 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 D</xref>
###xml 1603 1604 1603 1604 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1625 1626 1625 1626 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1787 1789 1787 1789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib56">56</xref>
###xml 1878 1879 1878 1879 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2070 2071 2070 2071 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2100 2102 2100 2102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib57">57</xref>
###xml 2111 2119 2111 2119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 E</xref>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
###xml 1249 1253 <span type="species:ncbi:10090">mice</span>
###xml 1905 1909 <span type="species:ncbi:10090">mice</span>
Lower T reg cell levels in the tumor could be explained, then, by a preferential lack of proliferation and/or survival. We found an increase in T reg cell proliferation in mice treated with the combination therapy, as shown by Ki67 staining (Fig. 7 A). Furthermore, in the TDLN of mice treated with the combination therapy, T reg cells down-regulated CD62L, indicating a higher activation phenotype (Fig. 7 B). CD62L down-regulation is typically accompanied by the migration of T cells to effectors sites. T reg cells present at the tumor site were all CD62L low regardless of treatment. We observed that T reg cells from mice treated with the combination therapy showed a greater down-regulation of CD25 in the TDLN, whereas in the tumor, T reg cells from both treatment groups were CD25 low (Fig. 7 C). Given that IL-2 signaling is required for T reg cell survival (54), we hypothesized that T reg cell-specific apoptosis caused by hyperactivation by the combination therapy accounts for lower intratumoral T reg cell infiltration. Bcl-2 down-regulation occurs at the early stages of programmed cell death and has been shown to be a marker of T reg cell apoptosis in vivo (55). Bcl-2 was significantly down-regulated on T reg cells in the TDLN of mice treated with the combination therapy (Fig. 7 D). Bcl-2 was unchanged on CD4+ and CD8+ T cell effector populations, indicating T reg cell-specific cell death (Fig. 7 D and not depicted). The expression of Bcl-2 in all T cell populations tested was lower in the tumor than in the TDLN. We observed only marginal increases in the frequency of Annexin V+ and active caspase 3+ T reg cells after combination therapy. As apoptotic cells should be rapidly removed by the scavenger system in vivo, detection of low levels might be expected (56). To increase detection sensitivity, we transferred congenic, CFSE-labeled, purified CD4+ T cells into B16-bearing mice that were pretreated with CTX and later injected with OX86 or control IgG. The combination therapy induced a significantly higher percentage of active caspase 3+ and viability dye-positive (57) cells (Fig. 7 E). These populations were primarily CFSE low, consistent with the previous finding of increased T reg cell proliferation after combination therapy (not depicted). Collectively, these results imply that lower levels of intratumoral T reg cells caused by CTX plus OX86 therapy occur as a result of specific hyperactivation and T reg cell-specific cell death.
###end p 38
###begin p 39
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The combination of CTX and OX86 increases T reg cell activation and apoptosis.</bold>
###xml 93 94 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 414 415 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 421 422 421 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 515 516 515 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 522 523 522 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 700 701 700 701 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 707 708 707 708 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 716 717 716 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 723 724 723 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 873 874 873 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1000 1001 1000 1001 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1009 1010 1009 1010 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1170 1171 1170 1171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1175 1176 1175 1176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1338 1339 1338 1339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1365 1366 1365 1366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1373 1374 1373 1374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
###xml 161 165 <span type="species:ncbi:10090">mice</span>
###xml 194 198 <span type="species:ncbi:10090">mice</span>
###xml 226 229 <span type="species:ncbi:10116">rat</span>
###xml 867 871 <span type="species:ncbi:10090">mice</span>
###xml 935 939 <span type="species:ncbi:10090">mice</span>
###xml 964 968 <span type="species:ncbi:10090">mice</span>
###xml 1043 1046 <span type="species:ncbi:10116">rat</span>
The combination of CTX and OX86 increases T reg cell activation and apoptosis. C57BL/6 mice (n = 3-5 per group) were inoculated with B16-Matrigel. On day 6, all mice received CTX. On day 7, the mice received a dose of OX86 or rat IgG. Single-cell suspensions were prepared on day 21 from tumors and TDLNs and were analyzed by flow cytometry. (A) Representative histogram of Ki67 intracellular staining gated on CD4+ Foxp3+ T cells (percentages are shown). (B, top) Representative plot of CD62L staining gated on CD4+ Foxp3+ T cells; (bottom) CD62L MFI of T reg cells in tumor or TDLN. (C) CD25 MFI of T reg cell in tumors and TDLNs. (D, top) Representative plot of Bcl-2 intracellular staining of CD4+ Foxp3+ and CD4+ Foxp3- T cells; (bottom) Bcl-2 MFI of T reg cells in tumors and TDLNs. Experiments were repeated four times with similar results. (E) C57BL/6 CD45.1 mice (n = 4 per group) were inoculated with B16-Matrigel. On day 6, mice received CTX. On day 7, mice were injected with purified CD4+, CD45.2+ CFSE-labeled cells, and OX86 or rat IgG. On day 12, single-cell suspensions were prepared from TDLN and analyzed by flow cytometry. Events were gated on CD45.2+ CD4+ cells. (right) Activated caspase 3 versus CFSE is shown; (left) ViD versus CFSE is shown (percentages are shown). One representative plot (P < 0.05 for the Foxp3+ CFSE low active Caspase 3+ or ViD+ population) of two independent experiments is shown. Horizontal bars represent means. *, P < 0.05; **, P < 0.005; and ***, P < 0.0005.
###end p 39
###begin title 40
DISCUSSION
###end title 40
###begin p 41
###xml 991 992 991 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1151 1155 <span type="species:ncbi:10090">mice</span>
In this paper, we provide evidence that a chemotherapeutic agent routinely used in the clinic (CTX) can greatly enhance the antitumor potency of a novel form of immunotherapy (OX40 engagement) in an aggressive tumor model in which neither therapy alone shows a significant antitumor effect. The combination of CTX and OX86 resulted in regression and long-term protection of established, poorly immunogenic tumors. Mechanistically, we found that killing of the tumor by CTX provides the antigen necessary to prime an antitumor immune response, and in this setting, OX86 greatly enhances effector T cell function. On closer examination, we found T reg cells to be an important target of the combination therapy. Surprisingly, OX86 administration alone expanded T reg cells in the periphery, an effect that was exacerbated in combination with CTX. In the tumor microenvironment, however, the combination therapy promoted a favorable T effector/T reg cell ratio by increasing the number of CD8 T+ cells and decreasing the number of T reg cells. We observed elevated levels of T cell activation together with elevated apoptotic markers on T reg cells from mice treated with the combination therapy, indicating that hyperactivation leads to T reg cell-specific apoptosis within the tumor microenvironment.
###end p 41
###begin p 42
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib58">58</xref>
###xml 325 329 <span type="species:ncbi:10090">mice</span>
Numerous studies have shown that alkylating drugs such as CTX can potentiate an antitumor immune response (58). Our data suggest that CTX-induced tumor destruction leading to antigen cross-presentation is a mechanism that contributes to the synergy of the combination therapy. This is because (a) tumor-bearing but not naive mice subjected to the combination therapy were able to mount detectable antigen-specific T cell responses to proteins expressed on B16, and (b) tumor-specific T cells (pmel-1) proliferated more vigorously with the combination therapy at the TDLN but not at a distant site. These results suggest that cross-presentation of antigen provided by damaged tumor is an effective way to generate an antitumor T cell response and does not require the laborious identification of antigenic tumor epitopes.
###end p 42
###begin p 43
###xml 466 467 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 475 476 475 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 655 658 655 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
Several observations indicate that T reg cells are a primary target of OX86 when CTX plus OX86 combination therapy is administered. First, after CTX administration, T reg cells modulated the expression of OX40 (the sole receptor of OX86), whereas the effect on other T cell subsets was minimal. Second, we found OX86-biotin to be bound primarily to T reg cells in the tumor, TDLN, and spleen after CTX administration, whereas only a small proportion was bound to CD8+ and CD4+ T cells. Third, we observed increased T reg cell expansion in the spleen and TDLN and decreased levels of T reg cell infiltration in the tumor, an effect that was lost in an OX40-/- background.
###end p 43
###begin p 44
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib59">59</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib60">60</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
When we examined the role of OX40 engagement on T reg cells, we found that OX86 injection preferentially expanded T reg cells in the periphery. Because OX40 engagement promotes the clonal expansion of T cells (26), it is conceivable that OX86 promotes T reg cell expansion because T reg cells are in a perpetually proliferative state. (59, 60). Additionally, T reg cells are the only OX40-expressing population in naive mice (31, 33, 34). Our observations are consistent with early reports showing that chronic OX40 engagement in mice overexpressing OX40L promotes higher T reg cell levels (31). It has also been reported that OX40 engagement on T reg cells can reduce Foxp3 levels in vitro (33). We observed no difference in Foxp3 expression levels after OX86 administration in any of our treatments. The reason for this discrepancy is yet to be determined, but the degree of TCR stimulation or cytokine milieu that occurs in vivo versus in vitro could account for this inconsistency. In addition, we found no difference in the suppressive function of OX86-expanded T reg cells in ex vivo assays.
###end p 44
###begin p 45
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib61">61</xref>
###xml 345 351 345 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">62</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib63">63</xref>
At certain doses or administration regimens, CTX preferentially depletes T reg cells (12, 13, 16, 61). At the higher doses such as those reported in this paper, CTX induced profound lymphopenia. As recovery takes place and T cells undergo homeostatic proliferation, T reg cells are proliferating more vigorously than other populations analyzed (Fig. 5). This may be because homeostatic proliferation is driven by self-MHC-peptide complexes (62), and because the T reg cell repertoire is skewed toward self (63), there are greater MHC-TCR interactions for T reg cells than for effector T cells. OX86 can provide co-stimulation to an already cycling population of cells. Therefore, the addition of OX86 will fuel T reg cell expansion even further.
###end p 45
###begin p 46
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib51">51</xref>
###xml 1314 1315 1314 1315 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1559 1561 1559 1561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib46">46</xref>
###xml 1563 1565 1563 1565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">52</xref>
###xml 1737 1739 1737 1739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib64">64</xref>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
###xml 1658 1662 <span type="species:ncbi:10090">mice</span>
Increased levels of T reg cells are typically associated with a negative prognosis in preclinical tumor models and cancer patients (51). It is therefore counterintuitive that OX86 and CTX results in the peripheral expansion of this population because the combination therapy provides such strong antitumor effects. To understand this apparent paradox, we measured T reg cell levels within the tumor microenvironment and found a striking decline in intratumoral T reg cell levels in mice subjected to the combination therapy. Our data indicate that this decline occurs in two phases: first, an antibody-independent phase occurs where CTX induces a profound depletion of T reg cells in the tumor microenvironment. It is plausible that actively proliferating T reg cells within the tumor microenvironment are particularly susceptible to the effects of CTX and T reg cell repopulation is locally delayed. Alternatively, CTX may eliminate cells present within the tumor stroma that are responsible for the recruitment, maintenance, and induction of T reg cells within the tumor. Second, at a later time point, tumors repopulate with T reg cells in the CTX plus IgG control, whereas with CTX plus OX86 there is still a deficiency of T reg cells in the tumor. This is concurrent with significant tumor infiltration of CD8+ effector T cells that causes a favorable shift in the T effector to T reg cell balance. A positive T effector/T reg cell ratio has been shown to be a hallmark of favorable disease prognosis and positively correlates with successful therapies (46, 52). Similar observations were recently reported by Gough et al., where OX86 administration in mice with immunogenic tumors promoted a favorable T effector/T reg cell ratio (64) .
###end p 46
###begin p 47
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib65">65</xref>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib65">65</xref>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
Closer examination of the tumor microenvironment revealed higher proliferation and activation of T reg cells resulting from combination therapy. T reg cells in the TDLN expressed higher Ki67 and lower CD62L levels in mice treated with the combination therapy, indicating higher proliferation and activation. Furthermore, T reg cells in the TDLN expressed lower levels of CD25. Given that IL-2 signaling is essential for T reg cell homeostasis, a loss of IL-2 sensitivity will limit T reg cell survival (65). Furthermore, T reg cells from mice lacking CD25 or IL-2 exhibit an activated phenotype, suggesting that CD25 down-regulation is characteristic of activated T reg cells under certain circumstances (65).
###end p 47
###begin p 48
###xml 228 229 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 237 238 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib63">63</xref>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
Therefore, we hypothesized that hyperactivation of T reg cells within the tumor microenvironment induces T reg cell-specific cell death. Indeed, we detected apoptosis specifically within the T reg cell population, but not in CD4+ and CD8+ T effectors in the TDLN when mice were treated with the combination of CTX and OX86. At the tumor site in our model, however, T reg cells were apoptotic regardless of treatment, consistent with the notion that T reg cells at effector sites down-regulate Bcl-2 and then die (63).
###end p 48
###begin p 49
###xml 453 454 449 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 482 484 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib66">66</xref>
Based on these results, we propose that the clinical measurement of peripheral T reg cells might not be of diagnostic value and that intratumoral levels are of greater importance when novel immunotherapies are evaluated. Behaviorally, T reg cells might expand or contract depending on the local milieu provided by differences in co-stimulation or cytokine stimuli. Recently, it was reported that OX40 engagement in combination with TNF-alpha induces CD4+ T cell apoptosis in vitro (66). Given that the tumor microenvironment is abundant in TNF-alpha and OX86 is bound primarily to T reg cells, it is conceivable that this is a potential mechanism for T reg cell-specific cell death.
###end p 49
###begin p 50
###xml 194 195 194 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 200 201 200 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib67">67</xref>
###xml 286 287 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 292 293 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib68">68</xref>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib55">55</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib69">69</xref>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib70">70</xref>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 421 426 <span type="species:ncbi:10090">mouse</span>
###xml 824 828 <span type="species:ncbi:10090">mice</span>
Notably, an imbalance in the ratio of T reg/T effector cells as a result of T reg cell-specific apoptosis has been reported in a variety of autoimmune diseases. Higher apoptosis was found in CD4+ CD25+ T reg cells from patients with type 1 diabetes (67), whereas elevated numbers of CD4+ CD25+ cells undergoing apoptosis in the thyroid are found in patients with autoimmune thyroid disease (68). In the nonobese diabetic mouse strain, T reg cell apoptosis correlates with diabetes onset as a result of IL-2 deficiency (55), whereas immune steatohepatitis caused by oxidative stress has been associated with a down-regulation of Bcl-2 and an increase in T reg cell apoptosis (69). Expression of the proapoptotic molecule Bax under the CD25 promoter leads to T reg cell apoptosis and increased susceptibility to vasculitis in mice (70). To our knowledge, this is the first study to report that potent antitumor immunity can be achieved by inducing T reg cell-specific apoptosis.
###end p 50
###begin p 51
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib71">71</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib72">72</xref>
###xml 249 250 249 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib73">73</xref>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib74">74</xref>
###xml 526 528 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib51">51</xref>
###xml 613 614 613 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 932 938 932 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
###xml 1067 1069 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
The suppressive function of T reg cells constitutes a major barrier to effective cancer immunotherapy. Most cancers "hijack" T reg cells to evade the immune response by active recruitment (2), local expansion (4, 71, 72), and conversion of naive CD4+ T cells (73, 74). Therefore, strategies that can remove or abrogate their function are highly desirable. Clinically, the elimination of T reg cells has been achieved by targeting CD25 using a fusion protein consisting of IL-2 linked to diphtheria toxin (enileukin diftitox) (51). This strategy has the unfortunate caveat of potentially eliminating activated CD25+ effector T cells as well. In this paper, we present evidence that induction of T reg cell-specific cell death is an attractive alternative to T reg cell elimination because, in addition to decreasing T reg cell levels, the CTX plus OX86 combination therapy can enhance the activation of T cell effectors, as shown in Fig. 2. Furthermore, intratumoral administration of OX86 has been shown to deactivate the suppressive function of T reg cells locally (34).
###end p 51
###begin p 52
###xml 451 459 <span type="species:ncbi:9606">patients</span>
Given the multifactorial nature of cancer as a disease, it is unlikely that a single therapy will be an efficacious treatment. For this reason, combining conventional cytotoxic therapy with immunotherapy is an attractive approach. A major advantage of the reported strategy is that it does not require ex vivo manipulation or a priori knowledge of tumor antigens to provide potent antitumor immunity. Hence, we expect it could be easily applicable in patients suffering from a variety of malignancies regardless of MHC restriction.
###end p 52
###begin p 53
Overall, we present a novel mechanism by which potent tumor immunity is attained with the combination of CTX and OX40 engagement and show that this treatment induces a favorable T effector/T reg cell ratio as a result of T reg cell-specific apoptosis within the tumor environment.
###end p 53
###begin title 54
MATERIALS AND METHODS
###end title 54
###begin title 55

###end title 55
###begin title 56
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice and tumor cell lines.
###end title 56
###begin p 57
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib48">48</xref>
###xml 419 423 419 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eGFP</sub>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib65">65</xref>
###xml 490 493 490 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib75">75</xref>
###xml 834 835 834 835 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1004 1005 1004 1005 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
###xml 309 324 <span type="species:ncbi:10090">transgenic mice</span>
###xml 424 428 <span type="species:ncbi:10090">mice</span>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
###xml 598 602 <span type="species:ncbi:10090">mice</span>
###xml 635 640 <span type="species:ncbi:10090">mouse</span>
###xml 767 771 <span type="species:ncbi:10090">mice</span>
###xml 1096 1100 <span type="species:ncbi:10090">mice</span>
All mouse procedures were performed in accordance with institutional protocol guidelines at Memorial Sloan-Kettering Cancer Center (MSKCC) under an approved protocol. C57BL/6J (8-10-wk-old females) and C57BL/6J Thy1.1 animals, and C57BL/6J CD45.1 animals were obtained from the Jackson Laboratory. pmel-1 TCR transgenic mice (Thy1.1) were a gift from N. Restifo (National Institutes of Health, Bethesda, MD) (48); Foxp3eGFP mice were provided by A. Rudensky (MSKCC, New York, NY) (65). OX40-/- mice were provided by N. Killeen (University of California, San Francisco, San Francisco, CA) (75). All mice were bred at MSKCC. The B16-F10 mouse melanoma line was originally obtained from I. Fidler (M.D. Anderson Cancer Center, Houston, TX) and passaged intradermally in mice several times to ensure tumor growth. Immunization with 5 x 104 B16-F10 cells was determined to be a lethal dose. For experiments where isolation of tumor lymphocytes was performed, B16-Matrigel was subcutaneously injected (2.5 x 105 B16-F10 cells in 0.2 ml of Matrigel Matrix Growth Factor Reduced; BD). Without treatment, mice bearing B16-Matrigel tumors survived up to days 14-16 after tumor challenge.
###end p 57
###begin title 58
Monoclonal antibodies and drug treatment.
###end title 58
###begin p 59
###xml 355 358 <span type="species:ncbi:10116">Rat</span>
###xml 476 479 <span type="species:ncbi:10116">rat</span>
OX86 hybridoma was obtained from the European Collection of Cell Cultures. FGK45 hybridoma was obtained from the American Type Culture Collection. 9D9 hybridoma was a gift of J.P. Allison (MSKCC, New York, NY). The antibodies were produced, purified, and biotinylated where indicated in the figures by the Monoclonal Antibody Core Facility at MSKCC. Anti-Rat IgG was purchased from Sigma-Aldrich and reconstituted in sterile PBS before use. For all treatments, 0.5 mg OX86 or rat IgG was administered. 0.25 mg FGK45 and 0.1 mg 9D9 were administered as a single dose, as indicated in the figures. Cyclophosphamide monohydrate (Sigma-Aldrich) mixed in sterile PBS was administered at 250 mg/kg. Both agents were administered as a single dose intraperitoneally.
###end p 59
###begin title 60
Antibodies, FACS analysis, and cell sorting.
###end title 60
###begin p 61
The following antibodies were used for flow cytometry analysis: CD8-PE-Texas red, CD4-PerCP, Ki67-FITC, CD44-Alexa Fluor 700, CD62L-Alexa Fluor 750, CD25-PE-Cy7, active caspase 3-biotin, strep-PE-Texas red, and CD3 functional grade (BD); and OX40-PE, Foxp3-allophycocyanin, Bcl-2-PE, and CD45.2-Alexa Fluor 750 (eBioscience). All antibodies were used according to the manufacturer's instructions with the recommended buffers. The Vybrant CFDA SE Cell Tracer kit (CFSE), DAPI, and the LIVE/DEAD Fixable Aqua Dead Cell Stain kit (ViD) were obtained from Invitrogen and used according to the manufacturer's instructions.
###end p 61
###begin p 62
###xml 373 379 <span type="species:ncbi:9913">bovine</span>
Samples from TDLNs, spleens, and tumors were mechanically dissociated to obtain a single-cell suspension. Splenocytes were depleted of erythrocytes with ACK lysing buffer (Invitrogen). Lymphocytes were isolated from tumors using Percoll (GE Healthcare) gradient centrifugation. Before staining, cells were treated with saturating anti-CD16/CD32 (BD) in staining buffer (2% bovine serum albumin and 10 mM EDTA in PBS) on ice for 15 min. Staining of surface antigens was performed in staining buffer on ice for 40 min. All intracellular staining was conducted using the Foxp3 fixation/permeabilization buffer (eBioscience) according to the manufacturer's instructions. Flow cytometry was performed on a flow cytometer (LSRII; BD). FlowJo software (version 8.6.2; Tree Star, Inc.) was used for all flow cytometry analysis. FACS sorting was conducted on a cell sorter (FACSDiva; BD).
###end p 62
###begin title 63
ELISPOT assay and peptides.
###end title 63
###begin p 64
###xml 158 161 158 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">181</sub>
###xml 200 201 200 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib76">76</xref>
###xml 243 246 243 246 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">522</sub>
###xml 257 258 257 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
Peptides were synthesized by Genemed Synthesis, Inc. and used at >80% purity, as confirmed by HPLC. Peptide from dopachrome tautomerase/tyrosinase-related DCT181 (sequence VYDFFVWL) is restricted by Kb (76). Tyrosinase-related protein 1, Tyrp1522, is an I-Ab-restricted peptide (sequence RYAYDYEELPNPNHS; unpublished data).
###end p 64
###begin p 65
###xml 278 279 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 286 287 266 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 488 489 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 493 494 473 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 512 513 492 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 517 518 497 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 569 570 549 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 654 655 634 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 835 836 807 808 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 861 862 833 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1139 1141 1091 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib77">77</xref>
###xml 68 73 <span type="species:ncbi:10090">mouse</span>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 1033 1038 <span type="species:ncbi:10090">mouse</span>
Multiscreen-IP plates (Invitrogen) were coated with 100 microl anti-mouse IFN-gamma antibody (10 mg/ml; clone AN18; Mabtech) in PBS, incubated overnight at 4degreesC, washed with PBS to remove unbound antibody, and blocked with RPMI 1640 plus 7.5% FBS for 2 h at 37degreesC. CD8+ or CD4+ T cells were harvested from pooled spleens from sacrificed mice (3-4 mice per group), purified using anti-CD8 or anti-CD4 MACS magnetic beads (Miltenyi Biotec), and plated at a concentration of 5 x 104 CD8+ T cells or 2 x 105 CD4+ T cells per well. For antigen presentation, 5 x 104 irradiated B16 cells, EL-4 leukemia cells (American Type Culture Collection), or 105 T cell-depleted irradiated splenocytes that had been pulsed with 10 microg/ml of peptide for 1 h were added to a final volume of 100 microl/well. After incubation for 20 h for CD8+ T cells and 48 h for CD4+ T cells at 37degreesC, plates were extensively washed with PBS plus 0.05% Tween and incubated for 2 h at 37degreesC with 100 microl/well of biotinylated antibody against mouse IFN-gamma (2 mg/ml; clone R4-6A2; Mabtech). Spot development was performed as previously described (77). Spots were counted with an automated ELISPOT reader system with KS 4.3 software (Carl Zeiss, Inc).
###end p 65
###begin title 66
Adoptive transfer experiments.
###end title 66
###begin p 67
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 62 63 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 121 122 121 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
In some experiments, animals received 2 x 106 CFSE-labeled CD8+ pmel-1 cells intravenously via the lateral tail vein. CD8+ T cells were purified (approximately98% pure) from pooled spleens and LNs from pmel-1 mice by positive selection using CD8a (Ly-2) microbeads (Miltenyi Biotec) according to the manufacturer's instructions. Purified cells were stained in PBS with 10 microM CFSE at 37degreesC for 10 min and quenched in complete media. The cells were washed twice in PBS before transfer.
###end p 67
###begin p 68
###xml 26 29 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 155 156 155 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
In other experiments, OX40-/- animals received 2 x 107 purified CD4+ T cells from OX40-/- or wild-type mice or 3 x 107 splenocytes from wild-type mice. CD4+ T cells were purified by MACS using CD4 (L3T4) microbeads (Miltenyi Biotec). Purity was confirmed by flow cytometry to be approximately98%.
###end p 68
###begin p 69
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 56 60 56 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eGFP</sub>
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 76 80 76 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eGFP</sub>
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
For the in vivo conversion assay, FACS-sorted CD4+ Foxp3eGFP+ and CD4+ Foxp3eGFP- cells were transferred into B16-Matrigel tumor-bearing mice pretreated with CTX and then treated with either OX86 or IgG.
###end p 69
###begin p 70
###xml 173 174 173 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 187 188 187 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
###xml 288 291 <span type="species:ncbi:10116">rat</span>
In vivo apoptosis experiments were performed by injecting CD45.1 mice with B16-Matrigel. 6 d later, the mice were injected with CTX. On day 7, the mice were injected with 107 purified CD4+ cells from CD45.2 mice labeled with 10 microM CFSE. 4 h later, the mice were injected with OX86 or rat IgG. On day 12, single-cell suspensions were prepared from DLNs and analyzed by flow cytometry.
###end p 70
###begin title 71
T reg cell suppression assays.
###end title 71
###begin p 72
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib78">78</xref>
###xml 108 109 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 114 115 114 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 247 248 247 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 344 345 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 492 493 484 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
T reg cell suppression assays were performed with a modified method from Thornton et al. (78). In brief, CD4+ CD25+ T reg cells were purified by MACS using a regulatory T cell isolation kit (Miltenyi Biotec) from spleens of treated animals. 5 x 104 T reg cells were co-cultured at a 1:1 ratio with CFSE-labeled (1 microg/ml) Thy1.1 congenic CD8+ T cells purified by MACS positive selection (Miltenyi Biotec) in the presence of 1 microg/ml of plate-bound anti-CD3 antibody. After 96 h, the CD8+ T cell proliferation was analyzed by flow cytometry.
###end p 72
###begin title 73
Statistical calculations.
###end title 73
###begin p 74
###xml 96 97 96 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Statistical differences between experimental groups were determined by the two-tailed Student's t test using Prism software (GraphPad Software, Inc.).
###end p 74
###begin title 75
Online supplemental material.
###end title 75
###begin p 76
Fig. S1 shows that the CTX plus OX86 combination therapy does not alter the suppressive capability of T reg cells in vivo. Fig. S2 shows that the blocking of peripheral T reg cell conversion does not cause reduced levels of intratumoral T reg cells after treatment with the combination therapy. Online supplemental material is available at .
###end p 76
###begin title 77
Supplementary Material
###end title 77
###begin title 78
[Supplemental Material Index]
###end title 78
###begin p 79
The authors wish to thank S. Terzulli and N. Kalb for assistance in the creation of this manuscript; and P. Gregor, S. Quezada, A. Sepulveda, and P. Savage for comments, careful reading, and editing of this manuscript.
###end p 79
###begin p 80
This work was supported by grants from the National Cancer Institute (R01 CA56821, P01 CA33049, and P01 CA59350), Swim Across America, the Lita Annenberg Hazen Foundation, the T.J. Martell Foundation, the Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Cancer Foundation for Research, and the Experimental Therapeutics Center of MSKCC; a Cancer Research Institute Predoctoral Fellowship; and a grant from the Medical Scientist Training Program (GM07739 to G.A. Rizzuto).
###end p 80
###begin p 81
The authors have no conflicting interests.
###end p 81
###begin article-title 82
Regulatory T cells, tumour immunity and immunotherapy.
###end article-title 82
###begin article-title 83
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
###end article-title 83
###begin article-title 84
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 66 69 <span type="species:ncbi:9606">men</span>
Regulatory T cells and tumour immunity - observations in mice and men.
###end article-title 84
###begin article-title 85
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
###end article-title 85
###begin article-title 86
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.
###end article-title 86
###begin article-title 87
###xml 114 122 <span type="species:ncbi:9606">patients</span>
Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients.
###end article-title 87
###begin article-title 88
###xml 74 79 <span type="species:ncbi:9606">human</span>
Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells.
###end article-title 88
###begin article-title 89
###xml 112 120 <span type="species:ncbi:9606">patients</span>
CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients.
###end article-title 89
###begin article-title 90
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.
###end article-title 90
###begin article-title 91
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
###end article-title 91
###begin article-title 92
Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity.
###end article-title 92
###begin article-title 93
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
###end article-title 93
###begin article-title 94
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response.
###end article-title 94
###begin article-title 95
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.
###end article-title 95
###begin article-title 96
Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.
###end article-title 96
###begin article-title 97
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.
###end article-title 97
###begin article-title 98
Costimulation of T cells by OX40, 4-1BB, and CD27.
###end article-title 98
###begin article-title 99
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.
###end article-title 99
###begin article-title 100
Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide.
###end article-title 100
###begin article-title 101
###xml 96 100 <span type="species:ncbi:10090">mice</span>
Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer.
###end article-title 101
###begin article-title 102
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
###end article-title 102
###begin article-title 103
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
###end article-title 103
###begin article-title 104
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.
###end article-title 104
###begin article-title 105
Combinations of anticancer drugs and immunotherapy.
###end article-title 105
###begin article-title 106
###xml 189 193 <span type="species:ncbi:10090">mice</span>
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
###end article-title 106
###begin article-title 107
TNF/TNFR family members in costimulation of T cell responses.
###end article-title 107
###begin article-title 108
OX40 signaling directly triggers the antitumor effects of NKT cells.
###end article-title 108
###begin article-title 109
###xml 123 127 <span type="species:ncbi:10090">mice</span>
Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice.
###end article-title 109
###begin article-title 110
Costimulation of CD8 T cell responses by OX40.
###end article-title 110
###begin article-title 111
Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
###end article-title 111
###begin article-title 112
Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells.
###end article-title 112
###begin article-title 113
Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.
###end article-title 113
###begin article-title 114
OX40 costimulation turns off Foxp3+ Tregs.
###end article-title 114
###begin article-title 115
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.
###end article-title 115
###begin article-title 116
Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells.
###end article-title 116
###begin article-title 117
Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.
###end article-title 117
###begin article-title 118
###xml 56 61 <span type="species:ncbi:9606">human</span>
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
###end article-title 118
###begin article-title 119
Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts.
###end article-title 119
###begin article-title 120
Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand.
###end article-title 120
###begin article-title 121
Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals.
###end article-title 121
###begin article-title 122
Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo.
###end article-title 122
###begin article-title 123
OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
###end article-title 123
###begin article-title 124
Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
###end article-title 124
###begin article-title 125
Engagement of the OX-40 receptor in vivo enhances antitumor immunity.
###end article-title 125
###begin article-title 126
###xml 80 86 <span type="species:ncbi:10090">murine</span>
Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models.
###end article-title 126
###begin article-title 127
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
###end article-title 127
###begin article-title 128
Combination antibody-based cancer immunotherapy.
###end article-title 128
###begin article-title 129
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
###end article-title 129
###begin article-title 130
Signaling through OX40 (CD134) breaks peripheral T-cell tolerance.
###end article-title 130
###begin article-title 131
Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis.
###end article-title 131
###begin article-title 132
Tregs and rethinking cancer immunotherapy.
###end article-title 132
###begin article-title 133
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
###end article-title 133
###begin article-title 134
Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy.
###end article-title 134
###begin article-title 135
A function for interleukin 2 in Foxp3-expressing regulatory T cells.
###end article-title 135
###begin article-title 136
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.
###end article-title 136
###begin article-title 137
Clearance of apoptotic and necrotic cells and its immunological consequences.
###end article-title 137
###begin article-title 138
Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry.
###end article-title 138
###begin article-title 139
The anticancer immune response: indispensable for therapeutic success?
###end article-title 139
###begin article-title 140
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state.
###end article-title 140
###begin article-title 141
Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease.
###end article-title 141
###begin article-title 142
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells.
###end article-title 142
###begin article-title 143
Heterologous immunity and homeostatic proliferation as barriers to tolerance.
###end article-title 143
###begin article-title 144
Regulatory T cells and immune tolerance.
###end article-title 144
###begin article-title 145
OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.
###end article-title 145
###begin article-title 146
Regulatory T cell lineage specification by the forkhead transcription factor foxp3.
###end article-title 146
###begin article-title 147
###xml 132 135 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Enhancement of OX40-induced apoptosis by TNF coactivation in OX40-expressing T cell lines in vitro leading to decreased targets for HIV type 1 production.
###end article-title 147
###begin article-title 148
At-risk and recent-onset type 1 diabetic subjects have increased apoptosis in the CD4+CD25+ T-cell fraction.
###end article-title 148
###begin article-title 149
Apoptosis-induced decrease of intrathyroidal CD4(+)CD25(+) regulatory T cells in autoimmune thyroid diseases.
###end article-title 149
###begin article-title 150
A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury.
###end article-title 150
###begin article-title 151
Higher expression of Bax in regulatory T cells increases vascular inflammation.
###end article-title 151
###begin article-title 152
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
###end article-title 152
###begin article-title 153
###xml 32 40 <span type="species:ncbi:9606">patients</span>
CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression.
###end article-title 153
###begin article-title 154
Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.
###end article-title 154
###begin article-title 155
Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta.
###end article-title 155
###begin article-title 156
Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40).
###end article-title 156
###begin article-title 157
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.
###end article-title 157
###begin article-title 158
Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay.
###end article-title 158
###begin article-title 159
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.
###end article-title 159
###begin p 160
Abbreviations used: CTX, cyclophosphamide; DLN, draining LN; MFI, mean fluorescence intensity; strep-PE, streptavidin-PE; TDLN, tumor DLN.
###end p 160

